This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CRISPR Gene Editing: Owning the Future of Medicine
by Kevin Cook
In the Century of Biology, it pays to own the future of curing disease at the root.
CRISPR (CRSP) Up on Promising Data for Gene Therapy CTX001
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows sustained response to treatment in patients with transfusion-dependent beta thalassemia as well as sickle cell disease. Shares rise.
Intellia (NTLA) Catches Eye: Stock Jumps 7.8%
by Zacks Equity Research
Intellia (NTLA) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks
by Zacks Equity Research
Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.
Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel
by Kevin Cook
Two women will share the Nobel prize for a gene editing technology that will change the world.
CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status
by Zacks Equity Research
CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.
CRISPR Stocks: Buy or Trade?
by Kevin Cook
Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 11.59% and 72.13%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron Gets FDA Nod for Dupixent 300 Mg Pre-Filled Pen
by Zacks Equity Research
Regeneron (REGN) wins FDA approval for a 300-mg, single-dose, pre-filled pen for asthma drug, Dupixent.
Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%
by Zacks Equity Research
Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.
Regeneron Expands Deal With Intellia for Hemophilia Treatments
by Zacks Equity Research
Regeneron (REGN) expands partnership with Intellia Therapeutics to co-develop potential hemophilia A and B treatments.
Intellia Therapeutics Inc (NTLA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics Inc (NTLA) delivered earnings and revenue surprises of -61.54% and -46.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Intellia Therapeutics, Inc. (NTLA) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -5.56% and 14.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Intellia (NTLA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.
Implied Volatility Surging for Intellia (NTLA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intellia (NTLA) stock based on the movements in the options market lately.
Has Intellia Therapeutics (NTLA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (NTLA) Outperforming Other Medical Stocks This Year?
Gene Therapy the Next Best Thing: Here's Why (Revised)
by Zacks Equity Research
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Gene Therapy the Next Best Thing: Here's Why
by Zacks Equity Research
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data
by Zacks Equity Research
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag
by Zacks Equity Research
The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.
Intellia Therapeutics, Inc. (NTLA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Intellia Therapeutics, Inc. (NTLA).
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 19.67% and 16.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?